Oxford Nanopore Technologies
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 150m | 176m | 262m | 224m | 246m | 313m | 400m |
% growth | 119 % | 17 % | 49 % | (15 %) | 10 % | 27 % | 28 % |
EBITDA | (73.4m) | (184m) | (80.4m) | (143m) | (154m) | (121m) | (77.1m) |
% EBITDA margin | (49 %) | (104 %) | (31 %) | (64 %) | (62 %) | (39 %) | (19 %) |
Profit | (80.8m) | (221m) | (120m) | (204m) | (224m) | (202m) | (166m) |
% profit margin | (54 %) | (125 %) | (46 %) | (91 %) | (91 %) | (64 %) | (41 %) |
EV / revenue | - | 39.4x | 8.6x | 9.2x | 4.1x | 3.7x | 3.2x |
EV / EBITDA | - | -37.8x | -28.1x | -14.4x | -6.6x | -9.6x | -16.6x |
R&D budget | 64.1m | 100m | 85.6m | 137m | - | - | - |
R&D % of revenue | 43 % | 57 % | 33 % | 61 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
$900k | Seed | ||
$10.3m | Series A | ||
£10.0m | Series B | ||
£11.8m | Growth Equity VC | ||
£17.4m | Series C | ||
$28.0m | Series C | ||
£25.0m | Series D | ||
N/A | £31.4m | Late VC | |
£40.0m | Secondary | ||
£56.4m | Secondary | ||
N/A | Secondary | ||
£70.0m | Late VC | ||
$126m Valuation: $1.2b | Growth Equity VC | ||
* | £100m Valuation: £1.5b 110.0x EV/LTM Revenues | Growth Equity VC | |
* | £50.0m Valuation: £1.5b 110.0x EV/LTM Revenues | Growth Equity VC | |
N/A | £80.2m Valuation: £1.7b 32.6x EV/LTM Revenues -25.9x EV/LTM EBITDA | Secondary | |
N/A | £29.3m | Growth Equity VC | |
* | N/A | £48.4m | Growth Equity VC |
£84.4m | Series H | ||
£195m Valuation: £2.5b 21.8x EV/LTM Revenues -44.6x EV/LTM EBITDA | Series H | ||
£150m Valuation: £2.5b 21.9x EV/LTM Revenues -44.8x EV/LTM EBITDA | Late VC | ||
N/A | £350m Valuation: £3.4b 29.9x EV/LTM Revenues -61.1x EV/LTM EBITDA | IPO | |
* | £70.0m | Post IPO Equity | |
* | £50.0m | Post IPO Equity | |
Total Funding | AUD1.9b |
Related Content
Recent News about Oxford Nanopore Technologies
EditOxford Nanopore Technologies is a biotech company that specializes in the development of nanopore sequencing technology. This technology is used to decode DNA and RNA, providing highly accurate genomic data. The company's technology is used by scientific researchers to answer questions about the biology of people, plants, animals, pathogens, and environments. It is also increasingly being used in applied settings such as healthcare and food safety.
The company's business model is based on selling its nanopore sequencing technology and related products, including flow cells, compatible devices, manual and automated library prep, and data analysis solutions. The technology provides real-time insights, allowing for faster results that don't require batching. This makes it accessible and affordable, with scalability that enables more use cases.
The company operates in the biotech market, serving clients in the scientific research community, healthcare sector, and food safety industry. Its technology is unique in that it offers any-length sequencing, from short to ultra-long native DNA and RNA reads. This provides richer insights as it captures more types of genetic variation.
In terms of financial performance, the company generates revenue through the sale of its products and services. It has also formed strategic partnerships, such as with Apple, to integrate its technology with the M3 silicon chip.
Keywords: Nanopore Sequencing, Genomic Data, Biotech, Scientific Research, Healthcare, Food Safety, DNA and RNA Decoding, Real-time Insights, Scalability, Technology Sales.